Joan M Nolla

Prof. Dr. Joan M Nolla

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2018 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
AJAntonio Julià
Antonio Julià
FLFrancisco Javier López-Longo
Francisco Javier López-Longo
JVJosé Javier Pérez Venegas
José Javier Pérez Venegas
SBSilvia Bonàs-Guarch
Silvia Bonàs-Guarch
ÀOÀlex Olivé
Àlex Olivé
AFAntonio Fernandez-Nebro
Antonio Fernandez-Nebro
Systemic lupus erythematosus (SLE) is a common systemic autoimmune disease with a complex genetic inheritance. Genome-wide association studies (GWAS) have significantly increased the number of significant loci associated with SLE risk. To date, however, established loci account for less than 30% of the disease heritability and additional risk variants have yet to be identified. Here we performed a GWAS followed by a meta-analysis to identify new genome-wide significant loci for SLE. We genotyped a cohort of 907 patients with SLE (cases) and 1524 healthy controls from Spain and performed imputation using the 1000 Genomes reference data. We tested for association using logistic regression with correction for the principal components of variation. Meta-analysis of the association results was subsequently performed on 7,110,321 variants using genetic data from a large cohort of 4036 patients with SLE and 6959 controls of Northern European ancestry. Genetic association was also tested at the pathway level after removing the effect of known risk loci using PASCAL software. We identified five new loci associated with SLE at the genome-wide level of significance (p < 5 × 10− 8): GRB2, SMYD3, ST8SIA4, LAT2 and ARHGAP27. Pathway analysis revealed several biological processes significantly associated with SLE risk: B cell receptor signaling (p = 5.28 × 10− 6), CTLA4 co-stimulation during T cell activation (p = 3.06 × 10− 5), interleukin-4 signaling (p = 3.97 × 10− 5) and cell surface interactions at the vascular wall (p = 4.63 × 10− 5). Our results identify five novel loci for SLE susceptibility, and biologic pathways associated via multiple low-effect-size loci.

19 December 2018 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
OGon behalf of the RELESSER Study Group
on behalf of the RELESSER Study Group
FGFrancisco Javier Narvaez Garcia
Francisco Javier Narvaez Garcia
HBHelena Borrell
Helena Borrell
FSFernando Sánchez-Alonso
Fernando Sánchez-Alonso
IRIñigo Rúa-Figueroa
Iñigo Rúa-Figueroa
JPJosé María Pego-Reigosa
José María Pego-Reigosa
The purpose of this study was to assess the prevalence, associated factors, and impact on mortality of primary respiratory disease in a large systemic lupus erythematosus (SLE) retrospective cohort. All adult patients in the RELESSER-TRANS (Registry of Systemic Lupus Erythematosus Patients of the Spanish Society of Rheumatology [SER], cross-sectional phase) registry were retrospectively investigated for the presence of primary pleuropulmonary manifestations. In total 3215 patients were included. At least one pleuropulmonary manifestation was present in 31% of patients. The most common manifestation was pleural disease (21%), followed by lupus pneumonitis (3.6%), pulmonary thromboembolism (2.9%), primary pulmonary hypertension (2.4%), diffuse interstitial lung disease (2%), alveolar hemorrhage (0.8%), and shrinking lung syndrome (0.8%). In the multivariable analysis, the variables associated with the development of pleuropulmonary manifestation were older age at disease onset (odds ratio (OR) 1.03, 95% confidence interval (CI) 1.02–1.04), higher SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) scores (OR 1.03, 95% CI 1.00–1.07), the presence of Raynaud’s phenomenon (OR 1.41, 95% CI 1.09–1.84), secondary antiphospholipid syndrome (OR 2.20, 95% CI 1.63–2.97), and the previous or concomitant occurrence of severe lupus nephritis, (OR 1.48, 95% CI 1.12–1.95) neuropsychiatric manifestations (OR 1.49, 95% CI 1.11–2.02), non-ischemic cardiac disease (OR 2.91, 95% CI 1.90–4.15), vasculitis (OR 1.81, 95% CI 1.25–2.62), hematological manifestations (OR 1.31, 95% CI 1.00–1.71), and gastrointestinal manifestations, excluding hepatitis (OR 2.05, 95% CI 1.14–3.66). Anti-RNP positivity had a clear tendency to significance (OR 1.32, 95% CI 1.00–1.75; P = 0.054). The development of pleuropulmonary manifestations independently contributes to a diminished survival (hazard ratio of 3.13). However, not all complications will influence the prognosis in the same way. Whereas the occurrence of pleural disease or pulmonary thromboembolism has a minimal impact on the survival of these patients, the remaining manifestations have a major impact on mortality. Except for pleural disease, the remaining respiratory manifestations are very uncommon in SLE (<4%). Pleuropulmonary manifestations independently contributed to a decreased survival in these patients.

10 February 2021 in Aging Clinical and Experimental Research
Verified
Journal Article
Open access
PDF file
ACAlfonso J. Cruz-Jentoft
Alfonso J. Cruz-Jentoft
SRSusana Romero-Yuste
Susana Romero-Yuste
ECEugenio Chamizo Carmona
Eugenio Chamizo Carmona
JNJoan M Nolla
Joan M Nolla
Introduction: Sarcopenia is defined by a loss of muscle mass and function associated with mortality, decreased physical performance, falls, and disability. Since chronic inflammation and decreased physical activity are risk factors for developing sarcopenia, it is critical to assess the role of sarcopenia in immune-mediated rheumatic diseases (IMRDs). Moreover, nutritional interventions are emerging as key modifiable and affordable options to improve physical performance in sarcopenia. Objective: The aim of this review is to critically summarize current information on the evidence linking nutritional interventions and sarcopenia in IMRDs. Methods: The search and selection of articles was performed in Medline, Dimensions.ai, Google Scholar, Cochrane Library, Epistemonikos, and Trip Database. The results were clustered into three areas: sarcopenia and IMRDs, sarcopenia and biological disease-modifying antirheumatic drugs (bDMARDs), and nutritional interventions for sarcopenia. Findings: Several cross-sectional studies have shown a higher prevalence of sarcopenia in IMRDs, such as rheumatoid arthritis. Although not fully established, evidence linking sarcopenia and other IMRDs (ankylosing spondylitis and systemic sclerosis) has been also described. For secondary sarcopenia prevention and treatment, bDMARDs’ administration proved efficacy in patients with rheumatoid arthritis. Furthermore, there is growing evidence linking nutrition to the prevention and treatment of sarcopenia. Evidence linking unfavourable results in nutritional risk assessment, insufficient intake of protein, vitamin D, antioxidant nutrients, and long-chain polyunsaturated fatty acids and sarcopenia have been reported. Conclusion: Given that sarcopenia and IMRDs have strong links, further research is needed to improve patient care.

1 March 2014 in Reumatología Clínica
Verified
Journal Article
Closed access
NBNoemi Busquets
Noemi Busquets
CVCarmen Gómez Vaquero
Carmen Gómez Vaquero
JMJesús Rodríguez Moreno
Jesús Rodríguez Moreno
DVDaniel Roig Vilaseca
Daniel Roig Vilaseca
FGFrancisco Javier Narvaez Garcia
Francisco Javier Narvaez Garcia
JNJoan M Nolla
Joan M Nolla

15 July 2022 in RMD Open
Verified
Journal Article
Open access
PDF file
MIMorales Ivorra
Morales Ivorra
FGFrancisco Javier Narvaez Garcia
Francisco Javier Narvaez Garcia
CGCarmen Gómez-Vaquero
Carmen Gómez-Vaquero
CMCarmen Moragues
Carmen Moragues
JNJoan M Nolla
Joan M Nolla
MMManuel Alejandro Marín-López
Manuel Alejandro Marín-López
Objectives Sensitive detection of joint inflammation in rheumatoid arthritis (RA) is crucial to the success of the treat-to-target strategy. In this study, we characterise a novel machine learning-based computational method to automatically assess joint inflammation in RA using thermography of the hands, a fast and non-invasive imaging technique. Methods We recruited 595 patients with arthritis and osteoarthritis, as well as healthy subjects at two hospitals over 4 years. Machine learning was used to assess joint inflammation from the thermal images of the hands using ultrasound as the reference standard, obtaining a Thermographic Joint Inflammation Score (ThermoJIS). The machine learning model was trained and tuned using data from 449 participants with different types of arthritis, osteoarthritis or without rheumatic disease (development set). The performance of the method was evaluated based on 146 patients with RA (validation set) using Spearman’s rank correlation coefficient, area under the receiver-operating curve (AUROC), average precision, sensitivity, specificity, positive and negative predictive value and F1-score. Results ThermoJIS correlated moderately with ultrasound scores (grey-scale synovial hypertrophy=0.49, p<0.001; and power Doppler=0.51, p<0.001). The AUROC for ThermoJIS for detecting active synovitis was 0.78 (95% CI, 0.71 to 0.86; p<0.001). In patients with RA in clinical remission, ThermoJIS values were significantly higher when active synovitis was detected by ultrasound. Conclusions ThermoJIS was able to detect joint inflammation in patients with RA, even in those in clinical remission. These results open an opportunity to develop new tools for routine detection of joint inflammation.

1 October 2020 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
FGFrancisco Javier Narvaez Garcia
Francisco Javier Narvaez Garcia
JLJudit Lluch
Judit Lluch
MMMaria Molina-Molina
Maria Molina-Molina
VVVanesa Vicens-Zygmunt
Vanesa Vicens-Zygmunt
PLPatricio Luburich
Patricio Luburich
JNJoan M Nolla
Joan M Nolla